Left Ventricular Dysfunction

FDA advisory committee recommends use of Coreg, based on CAPRICORN study

Published in Medical Letter on the CDC and FDA, February 9th, 2003

GlaxoSmithKline (GSK) announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously supported the use of the beta-blocking agent Coreg (carvedilol) in patients who have had a heart attack and who have left ventricular dysfunction.

This recommendation is based on data from the landmark CAPRICORN (CArvedilol Post InfaRction Survival ContRol in Left Ventricular DysfunctioN) trial, which showed that early long-term treatment with Coreg following a heart attack in patients with left ventricular dysfunction could reduce the risk of dying by 23%.

"The CAPRICORN trial is the first major study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-02-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry